Skip to main content

Table 4 Comparison between the two studied groups according to all complications (pancreatitis in 31 and 38 patients, bleeding in 5 and 6 cases, perforation in 0 and 3 cases, cholangitis in 20 and 2 cases, and cardiopulmonary complications in 6 and 3 cases and mortality in 25 and 2 cases) in cirrhotic and non-cirrhotic patients respectively

From: Safety, risk stratification, and cost of ERCP in patients with cirrhosis: a prospective controlled study

Complications

Cirrhotic (n = 150)

Non-cirrhotic (n = 150)

χ2

P

No.

%

No.

%

Pre–ERCP pancreatitis

      

 No ( 293)

147

98

146

97.3

0.667

FEp = 0.684

 Yes (7)

3

2

4

2.7

Post-ERCP pancreatitis

      

 No (231)

119

79.3

112

74.7

0.922

0.337

 Yes (69)

31

20.7

38

25.3

  Chemical (43)

19

12.7

24

16.0

0.679

0.410

  Clinical (26)

12

8.0

14

9.3

0.168

0.681

Bleeding

      

 No (289)

145

96.7

144

96.0

0.094

0.759

 Yes (11)

5

3.3

6

4.0

  From papilla (6)

4

2.7

2

1.3

0.680

FEp = 0.684

  During endoscopy from papilla (1)

1

0.7

0

0.00

1.003

FEp = 1.000

  Mass in antrum (1)

0

0.0

1

0.7

1.003

FEp = 1.000

  From mass in duodenum (1)

0

0.0

1

0.7

1.003

FEp = 1.000

  Ulcer in stomach (2)

0

0.0

2

1.3

2.013

FEp = 0.498

Perforation

      

 No (150)

150

100.0

147

98.0

3.030

FEp =0.247

 Yes (3)

0

0.0

3

2.0

Anesthesia

      

 No (291)

144

96.0

147

98.0

1.031

FEp = 0.501

 Yes (9)

6

4.0

3

2.0

  Desaturation (5)

3

2.0

2

1.3

0.203

FEp = 1.000

  Hypotension (4)

3

2.0

1

0.7

1.014

FEp = 0.622

Cholangitis

      

 No (278)

130

86.7

148

98.7

18.775*

< 0.001*

 Procedure related (22)

20

13.3

2

1.3

Outcome

      

 Improved (272)

125

83.3

147

98.0

19.065*

< 0.001*

 Died (28)

25

16.7

3

2.0

Days of admission

    

 Min.–max

0.25–23.0

0.25–23.0

-

< 0.001

 Mean ± SD.

4.81 ± 3.88

3.61 ± 3.88

 Median

4.0

3.0

  1. *significante